Industry Reports
The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
The ultimate guide to the complex web of interactions within the U.S. prescription distribution and reimbursement system more >
The 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
The most comprehensive tool for analyzing the economic and business realities of the U.S. pharmaceutical distribution industry. more >
From The Drug Channels Blog
Thursday, September 3, 2026
BlinkRx Insights: Beyond the Hub - Rethinking the Prescription Journey
Today's guest post comes from Geoffrey Chaiken and Matthew Chaiken, Co-founders of BlinkRx. Geoffrey and Matthew examine how efforts to improve patient access have contributed to more >
Tuesday, September 1, 2026
The Private Label Biosimilar Paradox in Medicare Part D
By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not more >